According to a study led by researchers at UCLA, the Alzheimer’s drug Leqembi would raise future costs for Medicare by $2 billion to $5 billion a year. Leqembi, sold for …
Study finds Alzheimer’s drug Leqembi would cost Medicare up to $5 billion a year Read More »
The MIND diet was developed in 2015 by Rush University nutritional epidemiologist Martha Clare Morris and her colleagues. The MIND diet is a scientifically proven eating plan that aims to …
MIND Diet Helps to Prevent Dementia and Alzheimer’s Disease Read More »
The FDA approved the new Alzheimer’s drug lecanemab (BAN2401), which will be sold under the brand name Leqembi developed by Eisai and Biogen last week for patients with mild cognitive …
First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 50 Care Centers in six Florida counties and services at 45+ major hospitals, has become the …
First Choice Neurology to Offer New Alzheimer’s Risk Test Read More »
A late-stage clinical trial was conducted by Biogen and Eisai and the new Alzheimer’s drug they are developing for Alzheimer’s disease slowed the rate of cognitive decline. New Alzheimer’s Drug …
Research Study Shows New Alzheimer’s Drug Slows Cognitive Decline Read More »
By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services …
Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »
Light the World in Teal is an annual program held in November as part of Alzheimer’s Awareness Month. People and places around the world “go teal” to raise awareness and …
Light the World in Teal for Alzheimer’s Awareness Read More »
Today is World Alzheimer’s Day. It’s a day to celebrate to create awareness about the disease and to reduce the stigmatization and lack of information surrounding dementia. While World Alzheimer’s …
World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain Read More »
Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as …
Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »
Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly …
First Florida Patient to Receive Biogen Aducanumab Infusion Read More »
